OncoPharm CASSIOPEIA Part 2
Sep 16, 2021
This discussion dives into the pivotal findings of the CASSIOPEIA Part 2 clinical trial, examining the role of daratumumab in treating myeloma after auto stem cell transplant. It tackles the effectiveness of this maintenance therapy and highlights critiques related to the trial's design. The ethical implications of using an observation control group spark thought-provoking debate, making for an engaging exploration of current myeloma treatments.
AI Snips
Chapters
Transcript
Episode notes
CASSIOPEIA Part 2 Setup
- The CASSIOPEIA Part 2 study randomized post-transplant multiple myeloma patients to daratumumab maintenance versus observation.
- It effectively created four treatment arms comparing induction and maintenance strategies involving daratumumab.
Daratumumab Maintenance Benefits Vary
- Daratumumab maintenance post-transplant significantly improves progression-free survival compared to observation.
- However, patients already receiving daratumumab during induction and consolidation did not gain additional PFS benefit from maintenance.
Daratumumab Upfront May Improve Survival
- Daratumumab given upfront appears to improve overall survival based on hazard ratios and death rates.
- Early data shows 7.6% death in daratumumab induction group versus 13.5% without, a meaningful survival difference.